The discovery of asprosin was supported by research on patients with rare mutation-induced neonatal progeroid syndrome (NPS), who are characterized by extreme thinness, lipodystrophy, and low calorie consumption and energy expenditure with a simultaneously lowered insulin level and euglycemia confirming high insulin sensitivity [7,8]. Here, INS is linked to lipodystrophy.